Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
30.07. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
29.07. | Virax Biolabs appoints Iain Miller as independent director | 1 | Investing.com | ||
18.07. | Virax Biolabs receives Nasdaq letter over non-compliance with minimum bid price rule | 4 | Seeking Alpha | ||
18.07. | Virax Biolabs receives Nasdaq minimum bid price deficiency notice | 1 | Investing.com | ||
18.07. | Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency | 127 | PR Newswire | LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the... ► Artikel lesen | |
VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
02.07. | Virax Biolabs Group Ltd - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
13.06. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
31.03. | Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating | 5 | Benzinga.com | ||
18.03. | Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | 155 | PR Newswire | LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on... ► Artikel lesen | |
18.03. | Virax Biolabs begins UK clinical study on T cell dysfunction | 1 | Investing.com | ||
13.03. | Virax Biolabs Presents Findings On T-Cell Dysfunction In Post-Acute Infection Syndromes | 1 | RTTNews | ||
13.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
13.03. | Virax Biolabs shares T-Cell dysfunction findings | 2 | Investing.com | ||
05.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
25.02. | EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency | 4 | Benzinga.com | ||
25.02. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
23.01. | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 543 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
13.01. | Cosmos Health Inc.: Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries | 389 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
23.09.24 | Cosmos Health Inc: Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits | 260 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
16.09.24 | Cosmos Health Inc.: Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar | 299 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,75 | 0,00 % | EQS-News: CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an
08.08.2025 / 02:15 CET/CEST
Für... ► Artikel lesen | |
EVOTEC | 6,338 | -2,64 % | Wendepunkt bei Evotec: Gelingt der Aktie damit jetzt ein Mega-Comeback? | Ein möglicher Deal mit dem Schweizer Pharmakonzern Sandoz würde dem deutschen Biotechunternehmen Evotec finanziellen Spielraum verschaffen. Meilensteinzahlungen und Umsatzbeteiligungen könnten dann... ► Artikel lesen | |
BAVARIAN NORDIC | 31,900 | -0,06 % | Bavarian Nordic A/S: Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance | COPENHAGEN, Denmark, July 31, 2025 - Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consideration... ► Artikel lesen | |
ASEP MEDICAL | 6,021 | -100,00 % | Asep Medical validiert seinen Sepset(ER) Diagnosetest bei Patienten in der führenden wissenschaftlichen Fachzeitschrift Nature Communications. | 27. Mai 2025 / IRW-Press / Asep Medical Holdings Inc. ("Asep Medical" oder das "Unternehmen") (CSE: ASEP) (OTCQB: SEPSF) (FWB: JJ80) freut sich
bekanntzugeben, dass seine Tochtergesellschaft... ► Artikel lesen | |
GINKGO BIOWORKS | 11,000 | -0,90 % | Ginkgo Bioworks ernennt Brian O'Sullivan zum Leiter des kommerziellen Bereichs der Automatisierungssparte | ||
EMERGENT BIOSOLUTIONS | 7,640 | +1,06 % | Emergent BioSolutions Board Member Sold $67K In Company Stock | ||
GENPREX | 1,820 | -100,00 % | Genprex, Inc.: Genprex Issues Stockholder Letter and Provides 2025 Corporate Update | Company Achieves Multiple Clinical Development Milestones in 2025
Patient Treatment Continues in Two Lung Cancer Clinical Trials
AUSTIN, Texas, Aug. 4, 2025 ... ► Artikel lesen | |
PALISADE BIO | 0,810 | +1,25 % | PALISADE BIO, INC. - 10-Q, Quarterly Report | ||
GRITSTONE BIO | 0,016 | -100,00 % | Gritstone bio, Inc. - 15-12G, Securities registration termination | ||
SIGA TECHNOLOGIES | 8,535 | -0,47 % | SIGA Technologies - A solid quarter for topline growth | Q225 was a strong quarter for SIGA, supported by material topline traction, with deliveries of $79m of oral and IV TPOXX to the US strategic national stockpile (SNS), fully servicing the order book... ► Artikel lesen | |
GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs: Nasdaq-Rüge wegen Unterschreitung des Mindestkurses | ||
ANNOVIS BIO | 2,355 | -0,21 % | Annovis Bio, Inc. - 10-Q, Quarterly Report | ||
SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
HUMACYTE | 1,930 | +2,66 % | Humacyte: Benchmark bestätigt Kaufempfehlung trotz Umsatzverfehlung | ||
SAGIMET BIOSCIENCES | 6,900 | -7,38 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial... ► Artikel lesen |